Endovasc Holds ``Kick Off'' Meeting with CRO Regarding its Upcoming Liprostin Trial.

HOUSTON -- Endovasc Inc. (OTCBB:EVSC), today announced that the Company has met with their project team at Synergos, the clinical research organization (CRO) that will oversee its upcoming Liprostin clinical trial to finalize the protocol for FDA submission. Additionally, Synergos reviewed a list of clinical sites for the trial and will begin contacting the sites to determine their willingness to join the study and assess potential enrollment.

"Based on the successful completion of a phase II trial, further studies of Liprostin are warranted. We are extremely pleased to be moving forward with the clinical development program for Liprostin and anticipate continued success in the clinical trial process. We will communicate additional developments to our shareholders in the very near future," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.

Endovasc's Liprostin is a liposome-encapsulated from of prostaglandin E-1 (PGE-1). PGE-1 is known to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. In a recently completed Phase II study in patients with peripheral vascular disease, Liprostin treatment significantly improved pain free walking distance. Early phase clinical studies suggest that an encapsulated formulation (Liprostin) can improve the therapeutic index of PGE-1, potentially positively impacting many areas of treatment such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants and arthritis.

About Synergos:

Synergos, Inc. a Contract Research Organization, provides comprehensive clinical research and development services, from study design through regulatory submission. Founded in 1991, Synergos, Inc. has gained substantial experience in pharmaceutical, medical device and biotechnology product development, with significant expertise in numerous therapeutic and diagnostic areas. To date, they have managed studies, analyzed data and produced reports for each type of regulatory submission required by the FDA, including multiple NDAs and PMAs.

About Endovasc, Inc.

Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation.

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor:

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.